Bahl & Gaynor Inc Bristol Myers Squibb CO Transaction History

Bahl & Gaynor Inc

$19.3 Billion
Q3 2024

A detailed history of Bahl & Gaynor Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bahl & Gaynor Inc holds 45,263 shares of BMY stock, worth $2.67 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

45,263

Previous 44,454 1.82%

Holding current value

$2.67 Million

Previous $1.85 Million 26.87%

% of portfolio

0.01%

Previous 0.01%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$39.66 - $51.75 $32,084 - $41,865	809 Added 1.82%	45,263 $2.34 Million
Q2 2024 Aug 07, 2024	SELL	$40.25 - $52.99 $4,588 - $6,040	-114 Reduced 0.26%	44,454 $1.85 Million
Q1 2024 May 10, 2024	BUY	$47.98 - $54.4 $56,760 - $64,355	1,183 Added 2.73%	44,568 $2.42 Million
Q4 2023 Feb 02, 2024	SELL	$48.48 - $57.85 $204,585 - $244,127	-4,220 Reduced 8.86%	43,385 $2.23 Million
Q3 2023 Nov 03, 2023	SELL	$57.89 - $64.73 $220,445 - $246,491	-3,808 Reduced 7.41%	47,605 $2.76 Million
Q2 2023 Aug 14, 2023	SELL	$63.71 - $70.74 $44,278 - $49,164	-695 Reduced 1.33%	51,413 $3.29 Million
Q1 2023 May 03, 2023	SELL	$65.71 - $74.53 $246,938 - $280,083	-3,758 Reduced 6.73%	52,108 $3.61 Million
Q4 2022 Feb 10, 2023	SELL	$68.48 - $81.09 $16,572 - $19,623	-242 Reduced 0.43%	55,866 $4.02 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $216 - $128,169	1,668 Added 3.06%	56,108 $3.99 Million
Q2 2022 Aug 08, 2022	SELL	$72.62 - $79.98 $7,262 - $7,998	-100 Reduced 0.18%	54,440 $4.19 Million
Q1 2022 May 12, 2022	SELL	$61.48 - $73.72 $10,943 - $13,122	-178 Reduced 0.33%	54,540 $3.98 Million
Q4 2021 Feb 10, 2022	SELL	$53.63 - $62.52 $16,732 - $19,506	-312 Reduced 0.57%	54,718 $3.41 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $127,807 - $149,709	2,160 Added 4.09%	55,030 $3.26 Million
Q2 2021 Aug 06, 2021	SELL	$61.91 - $67.42 $56,214 - $61,217	-908 Reduced 1.69%	52,870 $3.53 Million
Q4 2020 Feb 02, 2021	SELL	$57.74 - $65.43 $54,968 - $62,289	-952 Reduced 1.74%	53,778 $3.34 Million
Q3 2020 Nov 12, 2020	SELL	$57.43 - $63.64 $82,699 - $91,641	-1,440 Reduced 2.56%	54,730 $3.3 Million
Q2 2020 Aug 13, 2020	SELL	$54.82 - $64.09 $7,345 - $8,588	-134 Reduced 0.24%	56,170 $3.3 Million
Q1 2020 May 26, 2020	BUY	$46.4 - $67.43 $2.61 Million - $3.8 Million	56,304 New	56,304 $3.14 Million
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $2.67 Million - $3.89 Million	-57,616 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$49.21 - $64.19 $63,923 - $83,382	-1,299 Reduced 2.2%	57,616 $3.7 Million
Q3 2019 Nov 14, 2019	SELL	$42.77 - $50.71 $10,264 - $12,170	-240 Reduced 0.41%	58,915 $2.99 Million
Q2 2019 Aug 12, 2019	SELL	$44.62 - $49.34 $258,037 - $285,333	-5,783 Reduced 8.91%	59,155 $2.68 Million
Q1 2019 May 13, 2019	SELL	$45.12 - $53.8 $609,706 - $726,999	-13,513 Reduced 17.22%	64,938 $3.1 Million
Q4 2018 Feb 12, 2019	SELL	$48.76 - $63.23 $119,949 - $155,545	-2,460 Reduced 3.04%	78,451 $4.08 Million
Q3 2018 Nov 09, 2018	SELL	$55.19 - $62.25 $66,228 - $74,700	-1,200 Reduced 1.46%	80,911 $5.02 Million
Q2 2018 Aug 14, 2018	SELL	$50.53 - $62.98 $178,471 - $222,445	-3,532 Reduced 4.12%	82,111 $4.54 Million
Q1 2018 May 11, 2018	SELL	$59.92 - $68.98 $500,332 - $575,983	-8,350 Reduced 8.88%	85,643 $5.42 Million
Q4 2017 Feb 13, 2018	BUY	$59.94 - $65.35 $218,661 - $238,396	3,648 Added 4.04%	93,993 $5.76 Million
Q3 2017 Nov 13, 2017	SELL	$55.23 - $63.74 $1.94 Million - $2.23 Million	-35,050 Reduced 27.95%	90,345 $5.76 Million
Q2 2017 Aug 11, 2017	SELL	N/A	-3,250 Reduced 2.53%	125,395 $6.99 Million
Q2 2017 Aug 10, 2017	BUY	N/A	128,645	128,645 $7.52 Million

Others Institutions Holding BMY

# of Institutions

2,602

Shares Held

1.46B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bahl & Gaynor Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bahl & Gaynor Inc with notifications on news.

Account